CD40LG and lymphoplasmacytic lymphoma: The 5 patients who developed rituximab related flare-up effect had an underlying hemopathy: 2 lymphoplasmacytic lymphoma, 1 marginal zone lymphoma and 2 MGUS (one IgM and one IgG).